Evelo Biosciences Inc (OTCPK:EVLO)
$ 0.06 0 (0%) Market Cap: 1.14 Mil Enterprise Value: 17.82 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q2 2019 Evelo Biosciences Inc Earnings Call Transcript

Aug 06, 2019 / 12:30PM GMT
Release Date Price: $118 (+5.92%)
Operator

Good morning, and welcome to Evelo's Conference Call for Initial Data Results for Clinical Trials EDP1815 and EDP1066. (Operator Instructions)

At this time, I'd like to turn the call over to Stefan Riley of Evelo. Please proceed.

Stefan Riley

Thank you, operator. This morning, we issued a press release that outlines the topics that we plan to discuss today. This release is available at www.evelobio.com under the Investors tab.

Today in our call, Simba Gill, Evelo's CEO, together with Duncan McHale, our Chief Medical Officer, will review the positive data from EDP1815 and EDP1066 and their significance on the company's strategy and future clinical plans.

Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones for 2019 and 2020, the potential of any of our monoclonal microbials and clinical data, the timing and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot